Knopp Neurosciences Reports Presentation Of Encouraging Clinical Trends In A Phase 2 Study Of KNS-760704 In ALS
The two-part Phase 2 study found that KNS-760704 was safe and well-tolerated in ALS patients for up to nine months. The study results also showed trends suggesting the potential for improved outcomes in function and survival. Knopp emphasized that the compound remains early in its development and that further testing in large, long-term, well-controlled Phase 3 studies is required to establish the necessary evidence that the drug is both safe and effective for patients with ALS.
"Knopp is very encouraged by the results presented today in Berlin and, at the same time, we're acutely aware of the work that remains to be done," said Michael Bozik, M.D., the President and CEO of Knopp. "We look forward to confirming and extending these results in Phase 3 studies, which we hope to initiate in 2010." Knopp has formally engaged regulators in the U.S. and European Union to obtain scientific input on its planned Phase 3 program, including a scheduled meeting with the U.S. FDA in January 2010.
Added Dr. Cudkowicz: "The safety results and the trends in improved functional and survival outcomes observed in this study provide preliminary evidence supporting the ongoing evaluation of KNS-760704 in Phase 3 clinical trials."
The primary objective of the Phase 2 study was to assess the safety and tolerability of KNS-760704 in ALS subjects for up to nine months. Secondary objectives included measuring the clinical effects of KNS-760704 on functional decline and mortality. The two-part design of the study provided the opportunity to assess the effects of KNS-760704 in the same sample of ALS subjects in two randomized, double-blind treatment periods separated by a one-month placebo washout.
In Part 1 of the study, 102 subjects received daily doses of 50 mg, 150 mg, or 300 mg of KNS-760704 or placebo for 12 weeks. KNS-760704 showed a dose-dependent trend in slowing the rate of disease progression as measured by the difference in slopes of ALS Functional Rating Scale-Revised (ALSFRS-R) across treatment groups, with the greatest benefit observed in the 300 mg dose group.
In Part 2 of the study, 92 subjects were re-randomized to receive daily doses of 50 mg or 300 mg of KNS-760704 for 24 weeks. In addition to results again suggesting a dose-dependent trend in slowing the rate of disease progression as measured by the ALSFRS-R, there was also a trend toward a survival benefit in the 300 mg group compared with the 50 mg group. In an exploratory test combining mortality and functional outcomes, subjects in the 300 mg group had a significantly improved outcome compared with the 50 mg group.
KNS-760704 is a low molecular weight benzothiazole shown to improve mitochondrial function and to confer significant cellular protection in neurons under stress. The chirally pure form of the synthetic benzothiazole (6R)-2-amino-4,5,6,7-tetrahydro-6-(propylamino) benzothiazole, KNS-760704 is highly orally bioavailable, water soluble, renally excreted, and only moderately protein bound. The compound has received orphan drug designation from the U.S. Food and Drug Administration and the European Commission for the treatment of patients with ALS, as well as Fast Track designation from the FDA.
Amyotrophic lateral sclerosis, also known as Lou Gehrig's disease and Charcot's sclerosis, is a rapid, universally fatal neurodegenerative disorder characterized by progressive muscle weakness and wasting. ALS affects adults in the prime of life and creates a substantial burden for caregivers. U.S. prevalence is approximately 20,000 and the global incidence is approximately two per 100,000. Only one drug has been approved for the treatment of ALS. Life expectancy after symptom onset is usually three to five years.
About Knopp Neurosciences Inc.
Knopp Neurosciences, based in Pittsburgh, PA, USA, is a drug discovery and development company focused on delivering breakthrough treatments for neurological disorders through innovation, experience, and partnership. The company's lead product candidate is KNS-760704, an orally bioavailable small molecule in development for the treatment of ALS. Knopp's leadership includes experienced neuroscience drug development and discovery executives formerly associated with major pharmaceutical companies. Knopp's financing has been led by Saturn Capital Inc. of Boston as placement agent and Saturn Partners II as lead funder.
About the 20th International Symposium on ALS/MND (Berlin, Germany)
The International Symposium on ALS/MND is a unique annual event that brings together leading international researchers and health and social care professionals to present and debate key innovations in their respective fields. The International Symposium is firmly established as the premier forum for those interested in improving care, understanding disease pathogenesis and developing novel treatments for ALS/MND. The international exchange of knowledge and strategies is essential to provide the best possible care for people with ALS/MND and to bring us closer to a day when no one has to live with the devastating impact of ALS/MND. The Motor Neurone Disease (MND) Association in Northampton, United Kingdom, organises the International Symposium on ALS/MND. The 2009 event is being hosted by the Deutsche Gesellschaft für Muskelkranke e.V. (DGM) (German neuromuscular diseases Association).
Knopp Neurosciences Inc.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Inc., Knopp Neurosciences. "Knopp Neurosciences Reports Presentation Of Encouraging Clinical Trends In A Phase 2 Study Of KNS-760704 In ALS." Medical News Today. MediLexicon, Intl., 11 Dec. 2009. Web.
10 Dec. 2016. <http://www.medicalnewstoday.com/releases/173657.php>
Inc., K. (2009, December 11). "Knopp Neurosciences Reports Presentation Of Encouraging Clinical Trends In A Phase 2 Study Of KNS-760704 In ALS." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.